Amag Pharmaceuticals and Takeda Canada have announced that Health Canada granted marketing approval for intravenous (IV) Feraheme (ferumoxytol) Injection, that is used as an iron replacement therapy to treat iron deficiency anemia (IDA) in chronic kidney disease (CKD).
Takeda entered into an agreement with Amag to exclusively market Feraheme for all therapeutic applications in Canada.
Amag will receive a milestone payment of $3m, upon the first commercial sale of Feraheme in Canada.
Amag interim president and CEO Frank E Thomas said the approval by the agency is key milestone for the company and would bolster its efforts in expansion.
"To that end, we have marketing applications for ferumoxytol to treat IDA in adult CKD patients currently under review in other regions, including Europe," Thomas added.
?
there will be blood there will be blood how to cook a turkey ucla basketball walmart black friday sales walmart black friday sales michelle obama booed at nascar
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.